# EDGAR Filing Document

**Accession Number:** 0002114044
**File Stem:** 0001193125-26-197828
**Filing Date:** 2026-4
**Character Count:** 15297
**Document Hash:** 1fd6acbc4b1630e6aa25266500cc4473
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-197828.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001193125-26-197828

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**EFFECTIVENESS DATE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hemab Therapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0002114044
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 414241952
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295466
- **FILM NUMBER:** 26927187

**BUSINESS ADDRESS:**
- **STREET 1:** 101 MAIN STREET
- **STREET 2:** SUITE 1220
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 45 2138 7627

**MAIL ADDRESS:**
- **STREET 1:** 101 MAIN STREET
- **STREET 2:** SUITE 1220
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**As filed with the Securities and Exchange Commission on April 30, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-1**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## HEMAB THERAPEUTICS HOLDINGS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2836** | **41-4241952** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**101 Main Street, Suite 1220** 

**Cambridge, MA 02142** 

**(617) 553-3952** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Benny Sørensen, M.D., Ph.D.** 

**President and Chief Executive Officer** 

**Hemab Therapeutics Holdings, Inc.** 

**101 Main Street, Suite 1220** 

**Cambridge, MA 02142** 

**(617) 553-3952** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Cynthia T. Mazareas, Esq.**<br> **Scott N. Lunin, Esq.**<br> **Wilmer Cutler Pickering Hale and Dorr LLP**<br> **60 State Street**<br> **Boston, Massachusetts 02109**<br> **(617) 526-6000** | **Benjamin K. Marsh, Esq.**<br> **Kristopher D. Brown, Esq.**<br> **Justin S. Platt, Esq.**<br> **Goodwin Procter LLP**<br> **The New York Times Building**<br> **620 Eighth Avenue**<br> **New York, NY 10018**<br> **(212) 813-8800** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this registration statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-294989

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

This registration statement is being filed with respect to the registration of an aggregate of 2,012,500 additional shares of common stock, par value $0.0001 per share, of Hemab Therapeutics Holdings, Inc., a Delaware corporation, which includes 262,500 shares of common stock that the underwriters have the option to purchase, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-294989), which was declared effective by the Securities and Exchange Commission on April 30, 2026, are incorporated in this registration statement by reference.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| 5.1 | [Opinion of Wilmer Cutler Pickering Hale and Dorr LLP](d133636dex51.htm) |
| 23.1 | [Consent of EY Godkendt Revisionspartnerselskab, independent registered public accounting firm](d133636dex231.htm) |
| 23.2 | [Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)](d133636dex51.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to the signature page to the registrant's Registration Statement on Form S-1 (File No. 333-294989) filed with the Securities and Exchange Commission on April 10, 2026)](http://www.sec.gov/Archives/edgar/data/2114044/000119312526151378/d50309ds1.htm) |
| 107 | [Filing Fee Table](d133636dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 30th day of April, 2026.

---

| | |
|:---|:---|
| **Hemab Therapeutics Holdings, Inc.** | **Hemab Therapeutics Holdings, Inc.** |
| By: | /s/ Benny Sørensen, M.D., Ph.D. |
|  | Benny Sørensen, M.D., Ph.D.<br> *President and Chief Executive Officer* |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Benny Sørensen, M.D., Ph.D.<br> Benny Sørensen, M.D., Ph.D. | President and Chief Executive Officer, Director<br> (*Principal Executive Officer*) | April 30, 2026 |
| /s/ Mads Behrndt, M.Sc.<br> Mads Behrndt, M.Sc. | Chief Financial Officer<br> (*Principal Financial and Accounting Officer*) | April 30, 2026 |
| \*<br> John Maraganore, Ph.D. | Chair of the Board | April 30, 2026 |
| \*<br> Linda Bain | Director | April 30, 2026 |
| \*<br> Laura Tadvalkar, Ph.D. | Director | April 30, 2026 |
| \*<br> Akshay Vaishnaw, M.D., Ph.D. | Director | April 30, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Benny Sørensen, M.D., Ph.D. |
|  | Benny Sørensen, M.D., Ph.D.<br> *Attorney-in-fact* |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g133636g61j96.jpg)

+1 617 526 6000 (t)

+1 617 526 5000 (f)

wilmerhale.com

April 30, 2026

Hemab Therapeutics Holdings, Inc.

100 Main Street Suite 1220

Cambridge, MA 02142

Re: <u>Registration Statement on Form S-1</u>

Ladies and Gentlemen:

This opinion is furnished to you in connection with a Registration Statement on Form S-1 (the "Registration Statement") filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Rule 462(b) of the Securities Act, for the registration of 2,012,500 shares of Common Stock, $0.0001 par value per share (the "Shares"), of Hemab Therapeutics Holdings, Inc., a Delaware corporation (the "Company"), including 262,500 Shares issuable upon exercise of an option to purchase additional shares granted by the Company.

The Shares are to be sold by the Company pursuant to an underwriting agreement (the "Underwriting Agreement") to be entered into by and among the Company and Goldman Sachs & Co. LLC, Jefferies LLC, and Evercore Group L.L.C., as representatives of the several underwriters named in the Underwriting Agreement, the form of which has been incorporated by reference into the Registration Statement.

We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings and actions of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and Bylaws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

![LOGO](g133636g80k66.jpg)

------

![LOGO](g133636g61j96.jpg)

April 30, 2026

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption "Legal Matters." In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

---

| | |
|:---|:---|
| By: | /s/ Wilmer Cutler Pickering Hale and Dorr LLP |
|  | WILMER CUTLER PICKERING HALE AND DORR LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated February 27, 2026 (except for Note 16(a), as to which the date is April 10, 2026, and Note 16(b) and (c), as to which the date is April 27, 2026), with respect to the consolidated financial statements of Hemab ApS included in the Registration Statement (Form S-1 No. 333-294989) and related Prospectus of Hemab Therapeutics Holdings, Inc. for the registration of its common stock.

/s/ EY Godkendt Revisionspartnerselskab

Copenhagen, Denmark

April 30, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Hemab Therapeutics Holdings, Inc.**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.0001 per share | 457(a) | 2012500 | $18.00 | $36225000.00 | 0.0001381 | $5002.67 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $36225000.00  |  | $5002.67  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $5002.67  |

---

 **Offering Note** <br>

<sup>1</sup> The registrant previously registered securities with a proposed maximum aggregate offering price not to exceed $310,500,000 on a Registration Statement on Form S-1 (File No. 333-294989), which was declared effective by the Securities and Exchange Commission on April 30, 2026. In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $36,225,000.00 is hereby registered, which includes the shares of common stock that the underwriters have the option to purchase.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---